kabutan

Immuno-Biological Lab, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 5.2 times, Exceeds Full-Year Plan

Mon Feb 10, 2025 3:30 pm JST Earnings

4570 Immuno-Biological Laboratories Co., Ltd. 【J-GAAP】

Earnings Report

Immuno-Biological Laboratories Co., Ltd. <4570> [TSE Growth] announced its financial results after the market closed on February 10th (15:30). The consolidated ordinary profit for the cumulative third quarter of the fiscal year ending March 2025 (April to December) surged 5.2 times that of the same period last year, reaching 129 million yen. The progress rate toward the full-year plan of 120 million yen is 107.5%, already exceeding the target and also exceeding the same period of the previous year of 20.0%.

Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit/loss for the January to March period (4Q) is expected to turn into a loss of 9 million yen (compared to a profit of 100 million yen in the same period last year).

In the most recent three-month period, from October to December (3Q), the consolidated ordinary profit/loss turned to a profit of 65 million yen (compared to a loss of 5 million yen in the same period last year). The operating profit/loss margin drastically improved from -1.6% in the same period last year to 23.7%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Dec, 2022 554 18 -67 -76 -8.2 ー Feb 6, 2023 J-GAAP
Apr - Dec, 2023 548 10 25 20 2.2 20.0 Feb 2, 2024 J-GAAP
Apr - Dec, 2024 680 124 129 133 14.3 107.5 Feb 10, 2025 J-GAAP
YoY +24.1% +1,140.0% +416.0% +565.0% +548.0%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2023 451 91 95 160 17.3 0 May 14, 2024 J-GAAP
Oct - Mar, 2024 Guidance 481 52 56 44 4.7 0 Nov 11, 2024 J-GAAP
YoY +6.7% -42.9% -41.1% -72.5% -72.6%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 794 57 -149 -289 -31.1 0 May 12, 2023 J-GAAP
Mar, 2024 816 104 125 186 20.1 0 May 14, 2024 J-GAAP
Mar, 2025 Guidance 925 120 120 115 12.4 0 May 14, 2024 J-GAAP
YoY +13.4% +15.4% -4.0% -38.2% -38.4%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2023 183 -3 -5 -6 -0.7 -1.6 Feb 2, 2024 J-GAAP
Jan - Mar, 2024 268 94 100 166 17.9 35.1 May 14, 2024 J-GAAP
Apr - Jun, 2024 229 51 56 51 5.5 22.3 Aug 8, 2024 J-GAAP
Jul - Sep, 2024 215 17 8 20 2.2 7.9 Nov 11, 2024 J-GAAP
Oct - Dec, 2024 236 56 65 62 6.7 23.7 Feb 10, 2025 J-GAAP
YoY +29.0% － － － －

Related Articles